文档介绍：CIK治疗恶性肿瘤的研究进展及临床应用现状
发表时间:2010-08-17发表者:李丽(访问人次:42)
【摘要】用免疫活性细胞输注的过继免疫是肿瘤生物治疗的研究热点之一。此疗法不仅是常规
抗肿瘤治疗的补充,更是为晚期不宜手术或无法承受放疗化疗所带来的副作用的患者开辟了一个新的
治疗途径,成为人类抗击肿瘤最有希望的战略措施之一。CIK(Cytokine Induced Killer)是继LAK, TIL及
CD3AK细胞之后,具有细胞增殖倍数高、肿瘤杀伤能力强等特点的新一代过继免疫抗肿瘤细胞。本文上海455医院肿瘤伽玛刀治疗中心李丽
就CIK的特点,抗肿瘤机制,及临床应用现状等作一综述。
【关键词】 C IK; 过继免疫; 肿瘤治疗
The anti2tumor development of C IK and its clin ica l applica tion N IE xin , L IU kan2feng TENG shao xia .
China M edical University, Shenyang 110004 China
【Abstract】 Objective adop tive immunotherapy is one of the hotest subject in biotherapy of tumor.
This treatment is not only the supp lement to conventional therapy, but also app ly hope to peop le who can not
sustain the side effects of radiotherapy and chemotherapy any longer. C IK is a new generation of adop tive immu2
nocell . It has strong ability of p roliferation, and high efficiency in killing different tumor cells than LAK, TIL
and CD3AK cells. This review is focused on the character, anti2tumor mechanism, and clinical app lication
of CIK.
【Key words】 cytokine induced killer (C IK) ; secondary immunotherapy; tumor treatment
CIK(Cytokine Induced Killer)最初是指在正常人体外周血中只占1~5%的CD3 + CD56 +的T淋巴细胞。目前国内外制备的用于过继免疫治疗的CIK细胞,实际上是体外扩增出的以CD3 + CD56 +、CD3 + CD8 +为主的异质性细胞群[ 1 ]。该细胞群是在多种细胞因子如IL22、IFN2γ及某些单克隆抗体(Anti2CD3McAb)的刺激下,由从外周血、骨髓或脐血中分离出来的单个核细胞在体外培养扩增而成,具有广泛的非MHC限制的极强的溶瘤活性。
1 CIK与其他过继免疫细胞的比较